Form 4: Cytek Biosciences SVP Allen Poirson Reports Stock Transactions
SEC Form 4 Filing
Allen Poirson, SVP of Business and Corporate Development at Cytek Biosciences, reports the vesting of restricted stock units and subsequent tax withholding.
Summary
- On March 11, 2024, Allen Poirson, SVP of Business and Corporate Development at Cytek Biosciences, had restricted stock units (RSUs) vest, resulting in the acquisition of 3,338 shares.
- Following the vesting, 1,301 shares were withheld by Cytek Biosciences to satisfy tax obligations at a price of $7.22 per share.
- After these transactions, Poirson directly owns 51,055 shares of Cytek Biosciences common stock and 30,043 restricted stock units.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of stock transactions. It doesn't inherently indicate positive or negative sentiment about the company's performance.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives.
Stakeholder Impact
- Shareholders are informed about insider transactions, promoting transparency.
Key Dates
| Date | Description |
|---|---|
| 03/11/2024 | Date of transaction: vesting of restricted stock units and tax withholding. |
| 03/13/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.